Kodiak Sciences Inc

Kodiak Sciences Inc. (Nasdaq: KOD) is a pre-commercial, retina-focused biotechnology company developing next-generation intravitreal therapies for retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), diabetic retinopathy (DR), retinal vein occlusion (RVO), and macular edema secondary to inflammation (MESI). The company's proprietary Antibody Biopolymer Conjugate (ABC) Platform enables extended ocular half-life, designed to reduce treatment burden for patients. Kodiak's pipeline includes three late-stage programs: Zenkuda (tarcocimab tedromer), an anti-VEGF therapy with a BLA-ready profile across DR, RVO, and wet AMD that has completed four successful Phase 3 studies; KSI-501, a bispecific anti-IL-6/VEGF-trap therapy in Phase 3 development for wet AMD and DME; and KSI-101, a bispecific IL-6/VEGF protein in Phase 3 for MESI. Zenkuda and KSI-501 together target the approximately $15 billion anti-VEGF market. The company generates no product revenue and funds operations through capital raises. Updated Aug 13, 2026